Search research articles
Contact Us
Filters
Showing results (11-20 of 59) with videos related to
Page
of 6
Sort By:
Selective Cancer Therapeutics
|
January 1, 1991
Suppression of tumor vascular activity by radioantibody therapy: implications for multiple cycle treatments
R D Blumenthal, R M Sharkey, R Kashi, et al.
Journal of the National Cancer Institute
|
February 1, 1989
Reduction by anti-antibody administration of the radiotoxicity associated with 131I-labeled antibody to carcinoembryonic antigen in cancer radioimmunotherapy
R D Blumenthal, R M Sharkey, D Snyder, et al.
Cancer Research
|
February 1, 1990
Use of hematopoietic growth factors to control myelosuppression caused by radioimmunotherapy
R D Blumenthal, R M Sharkey, L M Quinn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 7, 2000
Regulation of tumour drug delivery by blood flow chronobiology
R D Blumenthal, L Osorio, R Ochakovskaya, et al.
Cancer Research
|
February 1, 1990
Biological considerations for radioimmunotherapy
R M Sharkey, R D Blumenthal, H J Hansen, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
May 14, 2003
Colonic tumor CEA, CSAp and MUC-1 expression following radioimmunotherapy or chemotherapy
D E Modrak, D V Gold, D M Goldenberg, et al.
International Journal of Cancer
|
January 27, 1997
Reduction in the duration of myelotoxicity associated with radioimmunotherapy with infusions of the hemoregulatory peptide, HP5b in mice
R M Alisauskas, D M Goldenberg, R M Sharkey, et al.
Breast Cancer Research and Treatment
|
April 1, 1988
Animal modeling of human breast tumors: limitations in the use of estrogen pellet implants
R D Blumenthal, J J Jordan, W H McLaughlin, et al.
Experimental Hematology
|
August 7, 1998
Myelosuppressive changes from single or repeated doses of radioantibody therapy: effect of bone marrow transplantation, cytokines, and hematopoietic suppression
R D Blumenthal, R Alisauskas, W Lew, et al.
Cancer
|
December 24, 1997
Defining the optimal spacing between repeat radioantibody doses in experimental models: is there an accurate measurement for hematopoietic recovery?
R D Blumenthal, R Alisauskas, M Juweid, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 59) with videos related to
Sort By:
Page
of 6
Selective Cancer Therapeutics
|
January 1, 1991
Suppression of tumor vascular activity by radioantibody therapy: implications for multiple cycle treatments
R D Blumenthal, R M Sharkey, R Kashi, et al.
Journal of the National Cancer Institute
|
February 1, 1989
Reduction by anti-antibody administration of the radiotoxicity associated with 131I-labeled antibody to carcinoembryonic antigen in cancer radioimmunotherapy
R D Blumenthal, R M Sharkey, D Snyder, et al.
Cancer Research
|
February 1, 1990
Use of hematopoietic growth factors to control myelosuppression caused by radioimmunotherapy
R D Blumenthal, R M Sharkey, L M Quinn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 7, 2000
Regulation of tumour drug delivery by blood flow chronobiology
R D Blumenthal, L Osorio, R Ochakovskaya, et al.
Cancer Research
|
February 1, 1990
Biological considerations for radioimmunotherapy
R M Sharkey, R D Blumenthal, H J Hansen, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
May 14, 2003
Colonic tumor CEA, CSAp and MUC-1 expression following radioimmunotherapy or chemotherapy
D E Modrak, D V Gold, D M Goldenberg, et al.
International Journal of Cancer
|
January 27, 1997
Reduction in the duration of myelotoxicity associated with radioimmunotherapy with infusions of the hemoregulatory peptide, HP5b in mice
R M Alisauskas, D M Goldenberg, R M Sharkey, et al.
Breast Cancer Research and Treatment
|
April 1, 1988
Animal modeling of human breast tumors: limitations in the use of estrogen pellet implants
R D Blumenthal, J J Jordan, W H McLaughlin, et al.
Experimental Hematology
|
August 7, 1998
Myelosuppressive changes from single or repeated doses of radioantibody therapy: effect of bone marrow transplantation, cytokines, and hematopoietic suppression
R D Blumenthal, R Alisauskas, W Lew, et al.
Cancer
|
December 24, 1997
Defining the optimal spacing between repeat radioantibody doses in experimental models: is there an accurate measurement for hematopoietic recovery?
R D Blumenthal, R Alisauskas, M Juweid, et al.
Page
of 6